Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Oxycodone hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for This injection has been prescribed for you by your doctor to relieve moderate to severe pain. It contains the active ingredient oxycodone which belongs to a group of medicines called strong analgesics or 'painkillers'. Oxycodone is indicated in adults only.
e Oxycodone Do not use Oxycodone:
If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (See section 3, If you stop using Oxycodone). Sleep-related breathing disorders Oxycodone can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Other medicines and Oxycodone Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription. If you use this injection with some other medicines, the effect of this injection or the other medicines may be changed. Concomitant use of opioids and benzodiazepines increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However if your doctor does prescribe benzodiazepines or related drugs with opioids the dosage and duration of concomitant treatment should be limited by your doctor. Please follow your doctor's dosage recommendation closely. It could be helpful to inform friends or relatives to be aware of sign and symptoms stated above. Contact your doctor when experiencing such symptoms. The risk of side effects increases, if you use antidepressants (such as citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine). These medicines may interact with oxycodone and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 38 °C. Contact your doctor when experiencing such symptoms.
Tell your doctor or pharmacist if you are taking:
This medicine contains oxycodone, which is an opioid. It can cause dependence and/or addiction. This medicine contains oxycodone which is an opioid medicine. Repeated use of opioid painkillers can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Oxycodone may lead to dependence, abuse and addiction, which may result in life-threatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. You might feel that you need to carry on taking your medicine, even when it doesn't help to relieve your pain. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent or addicted on Oxycodone if:
Driving and using machines This injection may cause a number of side effects such as drowsiness which could affect your ability to drive or use machinery (see section 4 for a full list of side effects). These are usually most noticeable when you first start using the injection, or when changing to a higher dose. If you are affected you should not drive or use machinery. This medicine can affect your ability to drive as it may make you sleepy or dizzy.
Oxycodone A doctor or nurse will usually prepare and administer the injection for you. The injection should be used immediately after opening. The dose and how often the injection is given may be adjusted according to the severity of your pain. Before starting treatment and regularly during treatment, your doctor will discuss with you what
2 mg of oral oxycodone is equivalent to 1 mg of parenteral oxycodone. It must be emphasised that this is a guide to the dose required. Inter‐patient variability requires that each patient is carefully titrated to the appropriate dose. The patient should be monitored closely until stable when switching opioid medications. Conversion of patients from IV morphine to IV oxycodone: In patients who have received IV morphine prior treatment with IV oxycodone, the daily dosage should be based on 1:1 equivalence ratio. It must be emphasised that this is a guide to the dose required. Inter patient variability requires that each patient is carefully titrated to the appropriate dose. The patient should be monitored closely until stable when switching opioid medications. Elderly patients: Elderly patients should be treated with caution. The lowest dose should be administered with careful titration to pain control. Patients with renal and hepatic impairment: The dose initiation should follow a conservative approach in these patients. The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation. Paediatric population: There are no data on the use of oxycodone injection in patients under 18 years of age.
SC (Infusion): Dilute in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections if required. A starting dose of 7.5 mg/day is recommended in opioid naïve patients, titrating gradually according to symptom control. Cancer patients transferring from oral oxycodone may require much higher doses (see below).
Use in non‐malignant pain: Opioids are not first‐line therapy for chronic non‐malignant pain, nor are they recommended as the only treatment. Types of chronic pain which have been shown to be alleviated by strong opioids include chronic osteoarthritic pain and intervertebral disc disease. The need for continued treatment in non‐malignant pain should be assessed at regular intervals.
Transferring patients between oral and parenteral oxycodone: The dose should be based on the following ratio:
Endocrine system: Opioids may influence the hypothalamic-pituitary-adrenal or gonadal axes.
you may expect from using Oxycodone, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also if you stop using Oxycodone). Adults (over 18 years of age) The usual starting dose is dependent upon how the injection is administered. The usual starting doses are as follows:
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Oxycodone Keep this medicine out of the sight and reach of children. Store this medicine in a locked safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them. This medicinal product does not require any special storage conditions. Do not freeze. Shelf life after first opening: After opening, this medicinal product should be used immediately. Shelf life after dilution: Chemical and physical in‐use stability has been demonstrated for 24 hours at 25 °C and at 2‐8 °C (after dilution with sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections). From a microbiological point of view the product should be used immediately. If not used immediately, in‐use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions. Do not use this medicine if you notice any visible signs of deterioration (e.g. particles). Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Any unused portion should be discarded immediately. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Oxycodone contains Oxycodone 10 mg/ml:
Oxycodone 50 mg/ml: All medicines can cause allergic reactions, although – The active substance is oxycodone hydrochloride. Each 1 ml ampoule contains 50 mg of oxycodone serious allergic reactions are rare. Tell your doctor hydrochloride (equivalent to 45 mg of oxycodone). immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face The other ingredients are citric acid monohydrate; or lips, rash or itching especially those covering sodium citrate, sodium chloride, sodium hydroxide your whole body. (for pH adjustment), hydrochloric acid, concentrated (for pH adjustment), water for injections. The most serious side effect is a condition where you breathe more slowly or weakly than expected What Oxycodone looks like and contents of the (respiratory depression). Tell your doctor pack immediately if this happens to you. Clear, colourless solution for injection/infusion, free As with all strong painkillers, there is a risk that you from visible particles. may become addicted or reliant on this injection. Oxycodone is produced in 1 ml or 2 ml colourless Very common side effects (may affect more than glass ampoules. Ampoules are marked with a specific colour ring 1 in 10 people)
18.09.2025. HUK/I/0/4
Instructions for use/handling Each ampoule is for single use in a single patient. The medicinal product should be used immediately after opening the ampoule and any unused portion should be discarded. Do not use if there are any visible signs of deterioration (e.g. particles). Chemical and physical in-use stability has been demonstrated for 24 hours at 25 °C and at 2‐8 °C. From a microbiological point of view, the product should be used immediately. If not used immediately, in‐use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
Oxycodone 10 mg/ml, undiluted or diluted to 1 mg/ml with sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections and Oxycodone 50 mg/ml, undiluted or diluted to 3 mg/ml with sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections, is Route of administration physically and chemically stable when in contact Subcutaneous injection or infusion. with representative brands of polypropylene or Intravenous injection or infusion. polycarbonate syringes, polyethylene or PVC tubing, and PVC or EVA infusion bags, over Incompatibilities a 24 hour period at room temperature (25 °C) and at Cyclizine at concentrations of 3 mg/ml or less, 2‐8 °C. when mixed with Oxycodone, either undiluted or Oxycodone, whether undiluted or diluted in the diluted with water for injections, shows no sign of infusion fluids used in these studies and contained precipitation over a period of 24 hours storage at in the various assemblies, does not need to be room temperature. Precipitation has been shown to protected from light. occur in mixtures with Oxycodone at cyclizine concentrations greater than 3 mg/ml or when diluted As well as product is compatible with following medicinal products: hyoscine butylbromide, with sodium chloride 9 mg/ml (0.9%) solution for hyoscine hydrobromide, dexamethasone sodium injection. However, if the dose of Oxycodone phosphate, haloperidol, midazolam hydrochloride, injection is reduced and the solution is sufficiently metoclopramide hydrochloride, levomepromazine diluted with water for injections, concentrations hydrochloride, glycopyrronium bromide, ketamine greater than 3 mg/ml are possible. It is hydrochloride. recommended that water for injections be used as a diluent when cyclizine and oxycodone hydrochloride are co‐administered either intravenously Inappropriate handling of the undiluted solution after opening of the original ampoule, or of the or subcutaneously as an infusion. diluted solutions may compromise the sterility of Prochlorperazine is chemically incompatible with the product. Oxycodone. Discontinuation of treatment: When a patient no longer requires therapy with oxycodone, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal.
Oxycodone Hydrochloride 50 mg/ml solution for injection/infusion comes as injection containing 50mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Oxycodone Hydrochloride 50 mg/ml solution for injection/infusion is oxycodone hydrochloride.
Medicines with the same active substance, strength and form include: OxyNorm 50 mg/ml, solution for injection or infusion, Shortec 50 mg/ml, solution for injection or infusion, Oxycodone Hydrochloride 50 mg/ml solution for injection or infusion. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Oxycodone Hydrochloride 50 mg/ml solution for injection/infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
For the treatment of moderate to severe pain in patients with cancer and postoperative pain.
For the treatment of severe pain requiring the use of a strong opioid.
Oxycodone is indicated in adults only.
Posology
The dose should be adjusted according to the severity of pain, the total condition of the patient and previous or concurrent medication.
Adults over 18 years:
The following starting doses are recommended. A gradual increase in dose may be required if analgesia is inadequate or if pain severity increases.
IV (Bolus): Dilute to 1 mg/ml in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections. Administer a bolus dose of 1 to 10 mg slowly over 1-2 minutes.
Doses should not be administered more frequently than every 4 hours.
IV (Infusion): Dilute to 1 mg/ml in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections.
A starting dose of 2 mg/hour is recommended.
IV (PCA): Dilute to 1 mg/ml in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections.
Bolus doses of 0.03 mg/kg should be administered with a minimum lock-out time of 5 minutes.
SC (Bolus): Use as 10 mg/ml concentration. Oxycodone 50 mg/ml dilute in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections. A starting dose of 5 mg is recommended, repeated at 4-hourly intervals as required.
SC (Infusion): Dilute in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections if required.
A starting dose of 7.5 mg/day is recommended in opioid naïve patients, titrating gradually according to symptom control.
Cancer patients transferring from oral oxycodone may require much higher doses (see below).
Transferring patients between oral and parenteral oxycodone:
The dose should be based on the following ratio: 2 mg of oral oxycodone is equivalent to 1 mg of parenteral oxycodone. It must be emphasised that this is a guide to the dose required. Inter-patient variability requires that each patient is carefully titrated to the appropriate dose. The patient should be monitored closely until stable when switching opioid medications.
Conversion of patients from IV morphine to IV oxycodone:
In patients who have received IV morphine prior treatment with IV oxycodone, the daily dosage should be based on 1:1 equivalence ratio. It must be emphasised that this is a guide to the dose required. Inter patient variability requires that each patient is carefully titrated to the appropriate dose. The patient should be monitored closely until stable when switching opioid medications.
Elderly patients:
Elderly patients should be treated with caution. The lowest dose should be administered with careful titration to pain control.
Patients with renal and hepatic impairment:
The dose initiation should follow a conservative approach in these patients. The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation (see section 5.2).
Paediatric population:
There are no data on the use of oxycodone injection in patients under 18 years of age.
Use in non-malignant pain:
Opioids are not first-line therapy for chronic non-malignant pain, nor are they recommended as the only treatment. Types of chronic pain which have been shown to be alleviated by strong opioids include chronic osteoarthritic pain and intervertebral disc disease.
Treatment goals and discontinuation:
Before initiating treatment with Oxycodone, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with oxycodone, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
Duration of treatment:
Oxycodone should not be used for longer than necessary.
For instructions on dilution of the medicinal product before administration, see section 6.6.
Method of administration
Subcutaneous injection or infusion.
Intravenous injection or infusion.
Hypersensitivity to oxycodone or to any of the excipients listed in section 6.1.
Oxycodone must not be used in any situation where opioids are contraindicated:
- known sensitivity to morphine or other opioids;
- severe respiratory depression with hypoxia;
- severe chronic obstructive lung disease;
- cor pulmonale;
- severe bronchial asthma;
- elevated carbon dioxide levels in the blood;
- paralytic ileus;
- acute abdomen;
- chronic constipation.
The major risk of opioid excess is respiratory depression. Caution must be exercised when administering oxycodone to the debilitated elderly; patients with severely impaired pulmonary function, patients with impaired hepatic or renal function; patients with myxedema, hypothyroidism, Addison's disease, toxic psychosis, prostate hypertrophy, adrenocortical insufficiency, alcoholism, delirium tremens, diseases of the biliary tract, pancreatitis, inflammatory bowel disorders, hypotension, hypovolaemia, raised intracranial pressure, head injury (due to risk of increased intracranial pressure) or patients taking MAO inhibitors.
Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs
Concomitant use of benzodiazepines and opioids may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing of sedative medicines such as benzodiazepines or related drugs with opioids should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe benzodiazepines concomitantly with opioids, the lowest effective dose should be used, and the duration of treatment should be as short as possible (see also general dose recommendation in section 4.2). The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their environment to be aware of these symptoms (see section 4.5).
Gastrointestinal disorders
Oxycodone should not be used where there is a possibility of paralytic ileus occurring. Should paralytic ileus be suspected or occur during use, Oxycodone should be discontinued immediately.
Hepatobiliary disorders
Oxycodone may cause dysfunction and spasm of the sphincter of Oddi, thus increasing the risk of biliary tract symptoms and pancreatitis. Therefore, oxycodone has to be administered with caution in patients with pancreatitis and diseases of the biliary tract.
Surgical procedures
Oxycodone should be used with caution pre- or intra-operatively and within the first 12-24 hours post-operatively.
As with all opioid preparations, oxycodone products should be used with caution following abdominal surgery as opioids are known to impair intestinal motility and should not be used until the physician is assured of normal bowel function.
Non-malignant pain
For appropriate patients who suffer with chronic non-malignant pain, opioids should be used as part of a comprehensive treatment programme involving other medications and treatment modalities. A crucial part of the assessment of a patient with chronic non-malignant pain is the patient's addiction and substance abuse history.
If opioid treatment is considered appropriate for the patient, then the main aim of treatment is not to minimise the dose of opioid but rather to achieve a dose which provides adequate pain relief with a minimum of side effects.
Endocrine system
Opioids may influence the hypothalamic-pituitary-adrenal or gonadal axes. Some changes that can be seen include an increase in serum prolactin and decreases in plasma cortisol and testosterone. Clinical symptoms may be manifest from these hormonal changes.
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Opioid Use Disorder (abuse and dependence)
Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as oxycodone.
Repeated use of Oxycodone may lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Oxycodone may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
Before initiating treatment with Oxycodone and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.
Patients will require monitoring for signs of drug-seeking behavior (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Tolerance
The patient may develop tolerance to the drug with chronic use and require progressively higher doses to maintain pain control. Prolonged use of this product may lead to physical dependence and a withdrawal syndrome may occur upon abrupt cessation of therapy.
Withdrawal syndrome
When a patient no longer requires therapy with oxycodone, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. The opioid abstinence or withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhoea, or increased blood pressure, respiratory rate or heart rate.
As with other opioids, infants who are born to dependent mothers may exhibit withdrawal symptoms and may have respiratory depression at birth.
Hyperalgesia
Hyperalgesia that will not respond to a further dose increase of oxycodone may occur, particularly in high doses. An oxycodone dose reduction or change to an alternative opioid may be required.
Alcohol
Concomitant use of alcohol and Oxycodone may increase the undesirable effects of Oxycodone; concomitant use should be avoided.
This medicinal product contains less than 1 mmol sodium (23 mg) per 1 ml, that is to say essentially 'sodium free'.
The concomitant use of sedative medicines such as benzodiazepines or related drugs such with opioids increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dosage and duration of concomitant use should be limited (see section 4.4).
Drugs which affect the CNS include, but are not limited to: tranquillisers, anaesthetics, hypnotics, antidepressants, non-benzodiazepine sedatives, phenothiazines, neuroleptic drugs, alcohol, other opioids, muscle relaxants and antihypertensives.
Concomitant administration of oxycodone with anticholinergics or medicines with anticholinergic activity (e.g. tricyclic anti-depressants, antihistamines, antipsychotics, muscle relaxants, anti-Parkinson drugs) may result in increased anticholinergic adverse effects. Oxycodone should be used with caution and the dosage may need to be reduced in patients using these medications.
MAO inhibitors are known to interact with narcotic analgesics. MAO inhibitors cause CNS excitation or depression associated with hypertensive or hypotensive crisis (see section 4.4). Oxycodone should be used with caution in patients administered MAO–inhibitors or who have received MAO inhibitors during the last two weeks (see section 4.4).
Concomitant administration of oxycodone with serotonin agents, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) may cause serotonin toxicity. The symptoms of serotonin toxicity may include mental-status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea). Oxycodone should be used with caution and the dosage may need to be reduced in patients using these medications.
Alcohol may enhance the pharmacodynamic effects of oxycodone, concomitant use should be avoided.
Oxycodone is metabolised mainly by CYP3A4, with a contribution from CYP2D6. The activities of these metabolic pathways may be inhibited or induced by various co-administered drugs or dietary elements.
CYP3A4 inhibitors, such as macrolide antibiotics (e.g. clarithromycin, erythromycin and telithromycin), azole-antifungals (e.g. ketoconazole, voriconazole, itraconazole, and posaconazole), protease inhibitors (e.g. boceprevir, ritonavir, indinavir, nelfinavir and saquinavir), cimetidine and grapefruit juice may cause a reduced clearance of oxycodone that could cause an increase of the plasma concentrations of oxycodone. Therefore the oxycodone dose may need to be adjusted accordingly.
Some specific examples are provided below:
• Itraconazole, a potent CYP3A4 inhibitor, administered 200 mg orally for five days, increased the AUC of oral oxycodone. On average, the AUC was approximately 2.4 times higher (range 1.5 - 3.4).
• Voriconazole, a CYP3A4 inhibitor, administered 200 mg twice-daily for four days (400 mg given as first two doses), increased the AUC of oral oxycodone. On average, the AUC was approximately 3.6 times higher (range 2.7 - 5.6).
• Telithromycin, a CYP3A4 inhibitor, administered 800 mg orally for four days, increased the AUC of oral oxycodone. On average, the AUC was approximately 1.8 times higher (range 1.3 - 2.3).
• Grapefruit Juice, a CYP3A4 inhibitor, administered as 200 ml three times a day for five days, increased the AUC of oral oxycodone. On average, the AUC was approximately 1.7 times higher (range 1.1 - 2.1).
CYP3A4 inducers, such as rifampicin, carbamazepine, phenytoin and St John's Wort may induce the metabolism of oxycodone and cause an increased clearance of oxycodone that could cause a reduction of the plasma concentrations of oxycodone. The oxycodone dose may need to be adjusted accordingly.
Some specific examples are provided below:
• St John's Wort, a CYP3A4 inducer, administered as 300 mg three times a day for fifteen days, reduced the AUC of oral oxycodone. On average, the AUC was approximately 50% lower (range 37-57%).
• Rifampicin, a CYP3A4 inducer, administered as 600 mg once-daily for seven days, reduced the AUC of oral oxycodone. On average, the AUC was approximately 86% lower.
Drugs that inhibit CYP2D6 activity, such as paroxetine and quinidine, may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations.
Use of this medicinal product should be avoided to the extent possible in patients who are pregnant or lactating, or during labour.
Pregnancy
There are limited data from the use of oxycodone in pregnant women. Infants born to mothers who have received opioids during the last 3 to 4 weeks before giving birth should be monitored for respiratory depression.
Withdrawal symptoms may be observed in the newborn of mothers undergoing treatment with oxycodone.
Breast-feeding
Oxycodone may be secreted in breast milk and may cause respiratory depression in the newborn. Oxycodone should, therefore not be used in breast-feeding mothers.
Fertility
No studies on fertility or the post-natal effects of intrauterine exposure have been carried out.
Oxycodone may impair the ability to drive and use machines. Oxycodone may modify patients' reactions to a varying extent depending on the dosage and individual susceptibility. Therefore patients should not drive or operate machinery, if affected.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
o The medicine has been prescribed to treat a medical or dental problem and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
o It was not affecting your ability to drive safely
Adverse drug reactions are typical of full opioid agonists. Tolerance and dependence may occur (see section 4.4). Constipation may be prevented with an appropriate laxative. If nausea or vomiting are troublesome, oxycodone may be combined with an antiemetic.
The following frequency categories form the basis for classification of the undesirable effects:
Very common
≥ 1/10
Common
≥ 1/100 to < 1/10
Uncommon
≥ 1/1 000 to < 1/100
Rare
≥ 1/10 000 to < 1/1 000
Very rare
< 1/10 000
Not known
Cannot be estimated from the available data
Immune system disorders:
Uncommon: hypersensitivity.
Frequency not known: anaphylactic reaction, anaphylactoid reaction.
Metabolism and nutrition disorders:
Common: decreased appetite.
Uncommon: dehydration.
Psychiatric disorders:
Common: anxiety, confusional state, depression, insomnia, nervousness, abnormal thinking, abnormal dreams.
Uncommon: agitation, affect lability, euphoric mood, hallucinations, decreased libido, drug dependence (see section 4.4), disorientation, mood altered, restlessness, dysphoria.
Frequency not known: aggression.
Nervous system disorders:
Very common: somnolence, dizziness, headache.
Common: tremor, lethargy, sedation.
Uncommon: amnesia, convulsion, hypertonia, hypoaesthesia, involuntary muscle contractions, speech disorder, syncope, paraesthesia, dysgeusia, hypotonia.
Frequency not known: hyperalgesia.
Eye disorders:
Uncommon: visual impairment, miosis.
Ear and labyrinth disorders:
Uncommon: vertigo.
Cardiac disorders:
Uncommon: palpitations (in the context of withdrawal syndrome), supraventricular tachycardia.
Vascular disorders:
Uncommon: vasodilatation, facial flushing.
Rare: hypotension, orthostatic hypotension.
Respiratory, thoracic and mediastinal disorders:
Common: dyspnoea, bronchospasm, cough decreased.
Uncommon: respiratory depression, hiccups.
Frequency not known: central sleep apnoea syndrome.
Gastrointestinal disorders:
Very common: constipation, nausea, vomiting.
Common: abdominal pain, diarrhoea, dry mouth, dyspepsia.
Uncommon: dysphagia, flatulence, eructation, ileus, gastritis.
Frequency not known: dental caries.
Hepatobiliary disorders:
Uncommon: increased hepatic enzymes, biliary colic.
Frequency not known: cholestasis, sphincter of Oddi dysfunction.
Skin and subcutaneous tissue disorders:
Very common: pruritus.
Common: rash, hyperhidrosis.
Uncommon: dry skin, exfoliative dermatitis.
Rare: urticaria.
Renal and urinary disorders:
Uncommon: urinary retention, ureteral spasm.
Reproductive system and breast disorders:
Uncommon: erectile dysfunction, hypogonadism.
Frequency not known: amenorrhoea.
General disorders and administration site conditions:
Common: asthenia, fatigue.
Uncommon: drug withdrawal syndrome, malaise, oedema, peripheral oedema, drug tolerance, thirst, pyrexia, chills.
Frequency not known: drug withdrawal syndrome neonatal.
Drug dependence
Repeated use of Oxycodone can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms of overdosage
Acute overdose with oxycodone can be manifested by miosis, respiratory depression, hypotension and hallucinations. Nausea and vomiting are common in less severe cases. Non-cardiac pulmonary oedema and rhabdomyolysis are particularly common after intravenous injection of opioid analgesics. Circulatory failure and somnolence progressing to stupor or coma, hypotonia, bradycardia, pulmonary oedema and death may occur in more severe cases. Toxic leukoencephalopathy has been observed with oxycodone overdose.
The effects of overdosage will be potentiated by the simultaneous ingestion of alcohol or other psychotropic drugs.
Treatment of overdosage
Primary attention should be given to the establishment of a patent airway and institution of assisted or controlled ventilation. The pure opioid antagonists such as naloxone are specific antidotes against symptoms from opioid overdose. Other supportive measures should be employed as needed.
In the case of massive overdosage, administer naloxone intravenously (0.4 to 2 mg for an adult and 0.01 mg/kg body weight for children) if the patient is in a coma or respiratory depression is present. Repeat the dose at 2 minute intervals if there is no response. If repeated doses are required then an infusion of 60% of the initial dose per hour is a useful starting point. A solution of 10 mg made up in 50 ml dextrose will produce 200 micrograms/ml for infusion using an IV pump (dose adjusted to the clinical response). Infusions are not a substitute for frequent review of the patient's clinical state.
Intramuscular naloxone is an alternative in the event that IV access is not possible. As the duration of action of naloxone is relatively short, the patient must be carefully monitored until spontaneous respiration is reliably re-established. Naloxone is a competitive antagonist and large doses (4 mg) may be required in seriously poisoned patients.
For less severe overdosage, administer naloxone 0.2 mg intravenously followed by increments of 0.1 mg every 2 minutes if required.
The patient should be observed for at least 6 hours after the last dose of naloxone.
Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to oxycodone overdosage. Naloxone should be administered cautiously to persons who are known, or suspected, to be physically dependent on oxycodone. In such cases, an abrupt or complete reversal of opioid effects may precipitate pain and an acute withdrawal syndrome.
Ask anything about Oxycodone Hydrochloride 50 mg/ml solution for injection/infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.